Targacept, Inc. (TRGT) Reports Fourth Quarter And 2013 Financial Results
2/13/2014 8:04:36 AM
WINSTON-SALEM, N.C.--(BUSINESS WIRE)--Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics™, today reported its financial results for the fourth quarter and year ended December 31, 2013. Targacept reported a net loss of $13.4 million for the fourth quarter of 2013, compared to a net loss of $15.9 million for the fourth quarter of 2012. For the year ended December 31, 2013, Targacept reported a net loss of $46.7 million, compared to a net loss of $7.0 million for 2012. As of December 31, 2013, cash and investments in marketable securities totaled $143.8 million.
Help employers find you! Check out all the jobs and post your resume.
comments powered by